MA
MLTX icon

Montag & Associates’s MoonLake Immunotherapeutics MLTX Stock Holding History

Montag & Associates’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7
Closed -$51 – 1082
2025
Q3 		$51 Buy
+7
New +$365 ﹤0.01% 1118

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Montag & Associates's MLTX Position: Q4 2025 in Review

Montag & Associates sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 7 shares — an estimated $51 sold.

Montag & Associates first reported a position in MLTX in Q3 2025 and held it in 1 quarter. The position peaked at $51 in Q3 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Montag & Associates reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Montag & Associates sold 7 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $51.
  • Montag & Associates first reported a position in MoonLake Immunotherapeutics in Q3 2025 and held it in 1 quarter.
  • Montag & Associates's MoonLake Immunotherapeutics position peaked at $51 in Q3 2025.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.